149 related articles for article (PubMed ID: 3257526)
21. The role of interleukin-2 in the biotherapy of cancer.
Parkinson DR
Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
[TBL] [Abstract][Full Text] [Related]
22. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group.
Dillman RO; Wiemann MC; Bury MJ; Church C; DePriest C
Cancer Biother Radiopharm; 1997 Feb; 12(1):5-11. PubMed ID: 10851441
[TBL] [Abstract][Full Text] [Related]
23. Continuous intravenous interleukin-2 infusion and subcutaneous interferon-alpha in metastatic renal cell carcinoma.
Fosså SD; Aune H; Baggerud E; Granerud T; Heilo A; Theodorsen L
Eur J Cancer; 1993; 29A(9):1313-5. PubMed ID: 8343275
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
25. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
Kuebler JP; Whitehead RP; Ward DL; Hemstreet GP; Bradley EC
J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
28. Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.
Stahel RA; Sculier JP; Jost LM; Delforge A; Bron D; Gmür J; Oelz O; Sauter C; Stryckmans P; Klastersky J
Eur J Cancer Clin Oncol; 1989 Jun; 25(6):965-72. PubMed ID: 2787749
[TBL] [Abstract][Full Text] [Related]
29. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.
Sosman JA; Kohler PC; Hank JA; Moore KH; Bechhofer R; Storer B; Sondel PM
J Natl Cancer Inst; 1988 Nov; 80(18):1451-61. PubMed ID: 3263508
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.
Triozzi PL; Kim JA; Martin EW; Young DC; Benzies T; Villasmil PM
J Clin Oncol; 1995 Feb; 13(2):482-9. PubMed ID: 7844609
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
[TBL] [Abstract][Full Text] [Related]
32. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
[TBL] [Abstract][Full Text] [Related]
33. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
35. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.
Thomas H; Barton C; Saini A; Dalgleish A; Waxman J
Eur J Cancer; 1992; 28A(6-7):1047-9. PubMed ID: 1627371
[TBL] [Abstract][Full Text] [Related]
36. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
Geertsen PF; Hermann GG; von der Maase H; Steven K
J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
38. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.
Lindemann A; Höffken K; Schmidt RE; Diehl V; Kloke O; Gamm H; Hayungs J; Oster W; Böhm M; Kolitz JE
Cancer Immunol Immunother; 1989; 28(4):275-81. PubMed ID: 2784715
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study.
Bauer M; Reaman GH; Hank JA; Cairo MS; Anderson P; Blazar BR; Frierdich S; Sondel PM
Cancer; 1995 Jun; 75(12):2959-65. PubMed ID: 7773948
[TBL] [Abstract][Full Text] [Related]
40. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
Shulman KL; Stadler WM; Vogelzang NJ
Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
